European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

[1]  Jinny Park,et al.  Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE) , 2020, British journal of haematology.

[2]  S. Pileri,et al.  Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study. , 2019, Blood.

[3]  B. Druker,et al.  Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. , 2019, The New England journal of medicine.

[4]  J. Radich,et al.  Meeting the needs of CML patients in resource-poor countries. , 2019, Hematology. American Society of Hematology. Education Program.

[5]  I. Flinn,et al.  Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis , 2019, Blood.

[6]  R. Foà,et al.  Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial , 2019, Blood.

[7]  T. Brümmendorf,et al.  Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study , 2019, Blood.

[8]  C. Craddock,et al.  FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial , 2019, Blood.

[9]  T. Brümmendorf,et al.  High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels , 2019, Blood.

[10]  S. Fujiwara,et al.  Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation. , 2019, Blood advances.

[11]  B. Kramer,et al.  Epidemiologic Signatures in Cancer. , 2019, The New England journal of medicine.

[12]  J. Lipton,et al.  The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission , 2019, Leukemia & lymphoma.

[13]  H. Kantarjian,et al.  Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. , 2019, The Lancet. Haematology.

[14]  J. Byrne,et al.  De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. , 2019, The Lancet. Haematology.

[15]  J. Lipton,et al.  The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia. , 2019, The Lancet. Haematology.

[16]  J. Reynolds,et al.  Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. , 2019, Blood advances.

[17]  G. Mufti,et al.  Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study. , 2019, The Lancet. Haematology.

[18]  J. Byrne,et al.  Initial reduction of therapy prior to complete treatment discontinuation in chronic myeloid leukaemia: final results of the British DESTINY Study , 2019 .

[19]  U. Olsson‐Strömberg,et al.  Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry , 2019, Bone Marrow Transplantation.

[20]  A. Turkina,et al.  Risks and challenges of CML management during pregnancy: Looking for a balanced decision , 2019, European journal of haematology.

[21]  Z. Estrov,et al.  Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. , 2019, Blood advances.

[22]  M. Baccarani,et al.  The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview , 2019, Leukemia.

[23]  C. Tam,et al.  The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia , 2019, Leukemia & lymphoma.

[24]  J. Hasford,et al.  Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV , 2018, Haematologica.

[25]  T. Brümmendorf,et al.  Pregnancy outcomes in patients treated with bosutinib , 2018, International journal of hematologic oncology.

[26]  M. Mauro,et al.  Back to the future: Treatment‐free remission and pregnancy in chronic myeloid leukemia , 2018, European journal of haematology.

[27]  J. Wason,et al.  Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML , 2018, Blood.

[28]  R. Foà,et al.  Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis , 2018, Blood.

[29]  R. Foà,et al.  The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients , 2018, Blood.

[30]  J. Gribben,et al.  Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. , 2018, The Lancet. Haematology.

[31]  C. Cleeland,et al.  A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors , 2018, Cancer medicine.

[32]  H. Kantarjian,et al.  Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value , 2018, Cancer.

[33]  J. Radich,et al.  Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[34]  Anna L. Brown,et al.  Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. , 2018, Blood.

[35]  J. Cortes,et al.  Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia , 2018, Haematologica.

[36]  Martin C. Müller,et al.  Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. , 2018, Blood.

[37]  Martin C. Müller,et al.  Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. , 2018, The Lancet. Oncology.

[38]  G. Chilov,et al.  Breastfeeding in Patients with Chronic Myeloid Leukaemia: Case Series with Measurements of Drug Concentrations in Maternal Milk and Literature Review , 2018, Mediterranean journal of hematology and infectious diseases.

[39]  N. Thielen,et al.  Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients , 2018, Leukemia.

[40]  J. Pinilla-Ibarz,et al.  Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study , 2018, Annals of Hematology.

[41]  T. McDonnell,et al.  Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. , 2017, Blood advances.

[42]  A. Salihoglu,et al.  Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec , 2017, Clinical lymphoma, myeloma & leukemia.

[43]  M. Konopleva,et al.  Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients , 2017, Cancer.

[44]  T. Brümmendorf,et al.  Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  T. Brümmendorf,et al.  Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy , 2017, Cancer.

[46]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[47]  Sukjoong Oh,et al.  Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia , 2017, Clinical Cancer Research.

[48]  T. Brümmendorf,et al.  Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants , 2017, Leukemia.

[49]  B. Leber,et al.  Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results , 2017, Leukemia.

[50]  C. Gambacorti-Passerini,et al.  Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. , 2017, European journal of cancer.

[51]  J. Góra‐Tybor,et al.  Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second‐Line Therapy: A Multicenter Prospective Observational Study , 2017, Clinical lymphoma, myeloma & leukemia.

[52]  A. Kurtovic-Kozaric,et al.  The Efficacy of Generic Imatinib as First‐ and Second‐line Therapy: 3‐Year Follow‐up of Patients With Chronic Myeloid Leukemia , 2017, Clinical lymphoma, myeloma & leukemia.

[53]  Francisco Cervantes,et al.  Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia , 2017, The New England journal of medicine.

[54]  P. Carlier,et al.  Erratum to: Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers , 2017, Archives of Gynecology and Obstetrics.

[55]  M. Baccarani,et al.  Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? , 2017, Nature Reviews Clinical Oncology.

[56]  W. Wiktor-Jedrzejczak,et al.  Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study , 2017, Leukemia.

[57]  M. Tulliez,et al.  Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. , 2017, Blood.

[58]  M. Tulliez,et al.  Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  U. Olsson‐Strömberg,et al.  Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era – a report from the Swedish CML register , 2017, European journal of haematology.

[60]  F. Efficace,et al.  The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. , 2016, Hematology. American Society of Hematology. Education Program.

[61]  Aaron N. Winn,et al.  Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Paul W Dickman,et al.  Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Jeroen J. Bax,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines , 2016, European journal of heart failure.

[64]  G. Lip,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). , 2016, European heart journal.

[65]  R. Silver,et al.  Management of CML-blast crisis. , 2016, Best practice & research. Clinical haematology.

[66]  M. Baccarani,et al.  Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. , 2016, Leukemia research.

[67]  P. Cony-Makhoul,et al.  CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment. , 2016, Leukemia research.

[68]  U. Olsson‐Strömberg,et al.  Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients , 2016, Leukemia.

[69]  N. Thielen,et al.  Chronic myeloid leukemia in the Netherlands: a population‐based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012 , 2016, European journal of haematology.

[70]  T. Hughes,et al.  Moving treatment-free remission into mainstream clinical practice in CML. , 2016, Blood.

[71]  H. Kantarjian,et al.  Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. , 2016, Blood.

[72]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[73]  J. Richter,et al.  The concept of treatment-free remission in chronic myeloid leukemia , 2016, Leukemia.

[74]  M. Baccarani,et al.  Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  T. Clackson,et al.  Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[76]  M. Baccarani,et al.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia , 2016, Leukemia.

[77]  Martin C. Müller,et al.  Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States , 2016, Journal of the National Cancer Institute.

[78]  I. Flinn,et al.  Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial , 2016, Leukemia.

[79]  N. Cordani,et al.  Chronic myeloid leukemia: Second‐line drugs of choice , 2016, American journal of hematology.

[80]  S. Mustjoki,et al.  Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients , 2015 .

[81]  S. Aksu,et al.  Generic Imatinib Mesylate is as Effective as Original Glivec in the Clinical Management of CML , 2015 .

[82]  J. Sakamoto,et al.  Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. , 2015, The Lancet. Haematology.

[83]  J. Cortes,et al.  The impact of dasatinib on pregnancy outcomes , 2015, American journal of hematology.

[84]  N. Schmitz,et al.  Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment , 2015, Leukemia.

[85]  W. Wiktor-Jedrzejczak,et al.  Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study , 2015, Leukemia.

[86]  Martin C. Müller,et al.  Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML , 2015, Annals of Hematology.

[87]  Martin C. Müller,et al.  Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. , 2015, Blood.

[88]  F. Gherlinzoni,et al.  Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib , 2015, Leukemia.

[89]  M. Konopleva,et al.  Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. , 2015, The Lancet. Haematology.

[90]  M. Baccarani,et al.  Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. , 2015, Blood.

[91]  C. Preudhomme,et al.  Analyzing molecular response in chronic myeloid leukemia clinical trials: Pitfalls and golden rules , 2015, Cancer.

[92]  K. Spiekermann,et al.  Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV , 2015, Leukemia.

[93]  D. Colomer,et al.  Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia , 2015, Leukemia.

[94]  P. Valent,et al.  Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. , 2015, Blood.

[95]  M. Baccarani,et al.  The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries , 2015, Leukemia.

[96]  M. Baccarani,et al.  Gimema Registry of Conception/Pregnancy in Adult Patients Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) , 2014 .

[97]  M. Baccarani,et al.  Impact of Dose Intensity of Ponatinib on Selected Adverse Events: Multivariate Analyses from a Pooled Population of Clinical Trial Patients , 2014 .

[98]  U. Olsson‐Strömberg,et al.  Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006) , 2014, European journal of haematology.

[99]  B. Leber,et al.  Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. , 2014, Blood.

[100]  U. Olsson‐Strömberg,et al.  Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  J. Hasford,et al.  Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase , 2014, Journal of Cancer Research and Clinical Oncology.

[102]  T. Brümmendorf,et al.  Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. , 2014, Blood.

[103]  Martin C. Müller,et al.  Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  J. Cayuela,et al.  Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  Aaron N. Winn,et al.  Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. , 2014, Journal of Clinical Oncology.

[106]  M. Baccarani,et al.  Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden , 2014, Haematologica.

[107]  H. Kantarjian,et al.  HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia , 2014, Cancer.

[108]  T. Clackson,et al.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. , 2013, The New England journal of medicine.

[109]  Francisco Cervantes,et al.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.

[110]  H. Jim,et al.  Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison , 2013, Supportive Care in Cancer.

[111]  J. Cortes,et al.  Re-emergence of interferon-α in the treatment of chronic myeloid leukemia , 2012, Leukemia.

[112]  Suzanne Kamel-Reid,et al.  A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. , 2012, Blood.

[113]  N. Cross,et al.  Standardized definitions of molecular response in chronic myeloid leukemia , 2012, Leukemia.

[114]  T. Brümmendorf,et al.  Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[116]  D. Marin,et al.  Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation , 2012, Haematologica.

[117]  Arnon Nagler,et al.  Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. , 2011, Blood.

[118]  J. Hasford,et al.  Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. , 2011, Blood.

[119]  A. Kohlmann,et al.  A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases , 2011, Leukemia.

[120]  Claude Preudhomme,et al.  Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. , 2010, The New England journal of medicine.

[121]  J. Radich,et al.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  J. Apperley.  Issues of imatinib and pregnancy outcome. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[123]  N. Cross.  Standardisation of molecular monitoring for chronic myeloid leukaemia. , 2009, Best practice & research. Clinical haematology.

[124]  G. Boysen,et al.  European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.

[125]  Martin C. Müller,et al.  Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. , 2008, Blood.

[126]  A. Ganser,et al.  Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia , 2007, Leukemia.

[127]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[128]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[129]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[130]  J. Hasford,et al.  A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. , 1998, Journal of the National Cancer Institute.

[131]  Francisco Cervantes,et al.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia , 1984 .

[132]  A S Spiers,et al.  METAMORPHOSIS OF CHRONIC GRANULOCYTIC LEUKAEMIA: DIAGNOSIS, CLASSIFICATION, AND MANAGEMENT , 1979, British journal of haematology.

[133]  Z. Estrov,et al.  Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia , 2019, Cancer.

[134]  H. Khoury,et al.  Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[135]  H. Khoury,et al.  Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[136]  M. Baccarani,et al.  Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia , 2016, Leukemia.

[137]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[138]  P. Cony-Makhoul,et al.  Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study. , 2015, The Lancet. Haematology.

[139]  J. Radich,et al.  Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study , 2013, Leukemia.

[140]  A. Hoes,et al.  [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.

[141]  H. Heimpel,et al.  Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia – prospective long-term results from a randomized-controlled trial , 2003, Leukemia.

[142]  M. Baccarani,et al.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia. , 1984, Blood.